The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 24, 2019
Filed:
Jul. 30, 2013
Applicant:
The Brigham and Women's Hospital, Inc., Boston, MA (US);
Inventors:
Richard S. Blumberg, Waltham, MA (US);
Vijay K. Kuchroo, Newton, MA (US);
Yu-Hwa Huang, Boston, MA (US);
Chen Zhu, Brookline, MA (US);
Ana C. Anderson, Brookline, MA (US);
Assignee:
The Brigham and Women's Hospital, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 38/10 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 38/10 (2013.01); A61K 39/3955 (2013.01); C07K 14/70503 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2319/30 (2013.01); Y02A 50/463 (2018.01); Y02A 50/466 (2018.01);
Abstract
Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.